Introduction {#s1}
============

Oesophagectomy is associated with a high burden of post-operative morbidity and mortality with attendant long-term health and economic costs \[[@C1]--[@C4]\]. Post-operative pulmonary complications including acute respiratory distress syndrome (ARDS) are common, and contribute significantly to the burden of post-operative morbidity and mortality \[[@C5], [@C6]\]. The reported incidence of ARDS post-oesophagectomy is variable and the reasons behind this heterogeneity are not clear. The reported incidence in the BALTI-P (Beta Agonist Lung Injury Trial Prevention) trial from which the cohort in this current study was drawn was 25.3% \[[@C7]\].

Smoking has recently been identified as a risk factor for the development of ARDS in nonpulmonary sepsis, following trauma and lung transplant \[[@C8]--[@C10]\]. The mechanism underlying this association is unclear, although cigarette smoke exposure is known to adversely alter the permeability of the pulmonary epithelium \[[@C11]\] and endothelium \[[@C12]\], and increase alveolar inflammation \[[@C13]\]. Recent evidence has demonstrated that smokers have an exaggerated disruption of the alveolar--capillary membrane and dysregulated cytokine release in response to nebulised *Escherichia coli* lipopolysaccharide compared with nonsmokers \[[@C14]\].

No clear association has been demonstrated between smoking and the risk of ARDS following oesophagectomy. This study compared pre- and post-operative plasma biomarkers, post-operative bronchoalveolar lavage (BAL) fluid biomarkers, and PiCCO system measures of alveolar oedema between smokers and nonsmokers undergoing oesophagectomy, aiming to assess the relationship between pre-operative smoking status and post-operative ARDS and mortality. It was hypothesised that current smokers would have higher BAL inflammatory markers, higher measures of alveolar oedema, and higher post-operative ARDS and mortality.

Methods {#s2}
=======

Study subjects {#s2a}
--------------

Data from ex-smokers and current smokers enrolled into a translational substudy of the BALTI-P trial were included \[[@C7], [@C15]\]. Patients with unresectable disease at surgery were excluded from analysis. Patients were asked to self-report their smoking status at the pre-operative assessment clinic 1--2 weeks prior to surgery. Current smokers were defined as patients who were self-reported cigarette smokers at the pre-operative assessment clinic. Ex-smokers were defined as patients who stated they had smoked in the past but no longer did so. The small number of patients who had never smoked were excluded from the analysis (n=6).

Data collection {#s2b}
---------------

Clinical and demographic data were collected prospectively from the patient\'s medical records. Full blood counts taken as part of routine clinical care were compared to investigate the level of systemic inflammation in the immediate post-operative period. Not all patients had blood drawn for full blood count on each post-operative day. BAL samples were collected at the end of the operation before extubation using the methods previously described \[[@C16]\]. Supernatant was extracted by centrifugation and analysed. The BAL supernatant was frozen at −80°C and batch analysis of levels of cytokines, including interleukin (IL)-1 receptor antagonist (IL-1ra), IL-1β, IL-6, IL-8, surfactant protein D (SPD), soluble receptor for advance glycation end-products (RAGE), tumour necrosis factor (TNF)-α, soluble TNF receptor-1 and -2 (TNFR1 and TNFR2), and vascular endothelial growth factor (VEGF), determined using Luminex technology (Millipore, Billerica, MA, USA). PiCCO readings (Pulsion, Feldkirchen, Germany), including cardiac index, extravascular lung water index (EVLWI) and pulmonary vascular permeability index (PVPI), were measured immediately pre-operatively, immediately post-operatively and on the morning after the operation (post-operative day 1). As this cohort of patients was diagnosed prior to the publication of the Berlin criteria, throughout the paper we have used ARDS to indicate patients meeting criteria for acute lung injury or ARDS according to the definition of the American European Consensus Conference \[[@C17]\].

Statistical analysis {#s2c}
--------------------

Data were analysed using Prism version 6 (GraphPad, La Jolla, CA, USA). Continuous data were analysed for normality using the D\'Agostino--Pearson omnibus normality test, and the appropriate parametric or nonparametric test was performed to detect differences in biochemical and clinical outcomes between current and ex-smokers at the time of the operation. Categorical data were assessed using the Chi-squared test. Survival was analysed using a Kaplan--Meier survival curve, the Gehan--Breslow--Wilcoxon test and log-rank hazard ratio assessment.

Results {#s3}
=======

50 patients (14 current smokers and 36 ex-smokers) were included. Baseline data comparisons between current and ex-smokers are summarised in [table 1](#TB1){ref-type="table"}. Current smokers were statistically more likely to be younger, with a lower body mass index (BMI) than ex-smokers. There was no significant difference in sex, forced expiratory volume in 1 s (FEV~1~) % pred or FEV~1~/forced vital capacity ratio between current and ex-smokers. There was no significant difference in any of three pre-operative risk assessment scores, *i.e.* modified Glasgow Prognostic Score, pre-operative neutrophil/lymphocyte ratio or pre-operative platelet/lymphocyte ratio.

###### 

Summary of baseline characteristics of current and ex-smokers at the time of operation

                                   **Ex-smokers**      **Current smokers**    **p-value**
  ---------------------------- ---------------------- ---------------------- -------------
  **Subjects**                           36                     14           
  **Male**                            31 (86)                13 (93)             0.663
  **Age years**                       65.5±9.7               51.9±8.1          \<0.0001
  **BMI kg·m^−2^**               26.0 (23.8--28.4)      22.0 (18.2--24.7)        0.002
  **FEV**~**1**~ **% pred**          82.8±23.3              93.1±21.2            0.153
  **FEV**~**1**~**/FVC %**       68.5 (61.9--75.4)      63.6 (52.4--70.3)        0.086
  **Pack-years**                    31.1 (17.7)            49.6 (30.5)           0.010
  **Histological diagnosis**                                                 
   Adenocarcinoma                    28 (77.7)               9 (64.3)            0.473
   Squamous                           8 (22.3)               5 (35.7)        
  **Tumour location**                                                        
   Lower oesophagus                   27 (75)                9 (64.2)            0.724
   Upper or mid oesophagus            6 (16.7)               3 (21.4)        
   Unknown                            3 (8.3)                2 (14.3)        
  **Cancer staging**                                                         
   IB, IIA or IIB                    15 (41.7)               6 (42.9)            0.939
   IIIA                              21 (58.3)               8 (57.1)        
  **ASA grade**                                                              
   2                                 26 (72.2)              13 (92.9)            0.148
   3--4                              10 (27.8)               1 (7.1)         
  **mGPS=1**                           5 (14)                 3 (21)             0.670
  **Pre-operative NLR**          2.75 (2.07--3.15)      2.61 (1.68--3.12)        0.479
  **Pre-operative PLR**         163.3 (130.7--207.3)   160.3 (113.4--252.6)      0.613

Data are presented as n, n (%), mean±[sd]{.smallcaps} or median (interquartile range), unless otherwise stated. BMI: body mass index; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; ASA: American Society of Anesthesiologists; mGPS: modified Glasgow Prognostic Score; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio.

Circulating neutrophil count {#s3a}
----------------------------

Current smokers had significantly higher numbers of circulating neutrophils on post-operative days 1--3 with no significant difference in lymphocyte or platelet count ([figure 1](#F1){ref-type="fig"}).

![Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. ^\#^: time-points were statistically significant using multiple t-tests with the Holm--Šídák method (α=5.0%) to account for multiple comparisons.](00089-2018.01){#F1}

Biochemical data {#s3b}
----------------

An insufficient BAL sample for analysis was obtained in one patient. Current smokers had higher numbers of alveolar macrophages in BAL fluid than ex-smokers (median (interquartile range (IQR)) 100 029 (40 178--178 043) *versus* 45 000 (24 146--73 260) cells·mL^−1^; p=0.025). In contrast to the plasma compartment, there was no significant difference in numbers of BAL neutrophils between current smokers and ex-smokers (median (IQR) 18 996 (1128--91 800) *versus* 4378 (740--90 909) cells·mL^−1^; p=0.517). Current smokers had significantly higher concentrations of IL-1ra (median (IQR) 51.0 (27.8--123.8) *versus* 10.1 (0.2--64.6) pg·mL^−1^; p=0.008) and TNFR1 (median (IQR) 270.5 (168.5--367.3) *versus* 166.8 (112.4--253.1) pg·mL^−1^; p=0.030), and significantly lower levels of VEGF (median (IQR) 94.1 (24.0--184.1) *versus* 151.0 (104.4--280.4) pg·mL^−1^; p=0.018) in BAL fluid compared with ex-smokers ([figure 2](#F2){ref-type="fig"}). Current smokers had significantly higher pre-operative plasma concentrations of soluble intercellular adhesion molecule (ICAM)-1 than ex-smokers (median (IQR) 103.5 (63.9--133.0) *versus* 56.0 (35.1--86.4) pg·mL^−1^; p=0.003), but there was no significant difference post-operatively. Plasma concentrations of IL-17 were generally lower in current smokers than ex-smokers, with a significant difference post-operatively (median (IQR) 2.64 (0.52--182.8) *versus* 36.8 (6.12--192.6) pg·mL^−1^; p=0.043). There was no significant difference in levels of total protein, soluble RAGE, SPD, IL-6, IL-8, IL-1β, TNF-α or TNFR2 between the groups ([supplementary tables E1--E4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00089-2018.figures-only#fig-data-supplementary-materials)).

![There was no difference in bronchoalveolar lavage (BAL) a) neutrophil counts between current smokers (n=14) and ex-smokers (n=35), but current smokers had significantly higher concentrations of b) macrophages, c) interleukin-1 receptor antagonist (IL-1ra) and d) tumour necrosis factor receptor-1 (TNFR1), and lower concentrations of e) vascular endothelial growth factor (VEGF), than ex-smokers.](00089-2018.02){#F2}

PiCCO measures of alveolar oedema {#s3c}
---------------------------------

EVLWI, PVPI and the arterial oxygen tension (*P*~aO~2~~)/inspiratory oxygen fraction (*F*~IO~2~~) ratio were similar between both groups pre- and post-operatively ([figure 3](#F3){ref-type="fig"}). EVLWI (median (IQR) 9.80 (7.80--12.18) *versus* 7.90 (6.25--10.25) mL·kg**^−^**^1^; p=0.026) and PVPI (median (IQR) 2.09 (1.78--2.50) *versus* 1.70 (1.45--2.01); p=0.013) were significantly higher in current smokers than ex-smokers on post-operative day 1. There was no significant difference in the *P*~aO~2~~/*F*~IO~2~~ ratio on post-operative day 1 (mean±[sd]{.smallcaps} current smokers 36.7±10.7 *versus* ex-smokers 42.8±10.7 kPa; p=0.072). There was no significant difference in the cardiac index at any time-point ([supplementary table E5](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00089-2018.figures-only#fig-data-supplementary-materials)).

![Current smokers had higher a) extravascular lung water index (EVLWI) and b) pulmonary vascular permeability index (PVPI) on post-operative day 1 than ex-smokers, but there was no significant difference in c) arterial oxygen tension (*P*~aO~2~~)/inspiratory oxygen fraction (*F*~IO~2~~) ratio.](00089-2018.03){#F3}

Clinical outcomes {#s3d}
-----------------

Of the 50 patients, 33 (66%) patients required ventilation after surgery with a median positive end-expiratory pressure of 5 cmH~2~O. On post-operative day 1 only three (6%) patients remained ventilated after surgery. There was no significant difference between groups in the requirement for ventilation after surgery (23 (64%) ex-smokers *versus* 10 (71%) current smokers; p=0.75) or on post-operative day 1 (two (6%) ex-smokers *versus* one (7%) current smoker; p=1.0). There was no significant difference between the intra-operative fluid balance between the two groups (median (IQR) ex-smokers 2330 (1888--3375) mL *versus* current smokers 2400 (1189--3088) mL; p=0.347).

A total of 17 patients (34%) developed ARDS post-operatively. Eight (57%) current smokers developed ARDS post-operatively compared with nine (25%) ex-smokers (p=0.031) ([figure 4](#F4){ref-type="fig"}). There was no significant difference in the risk of post-operative pneumonia between current smokers and ex-smokers (35.7% *versus* 27.8%; p=0.582). There was also no significant difference in the length of hospital admission between current smokers and ex-smokers (median (IQR) 14 (8--25) *versus* 15 (10--25) days; p=0.4487).

![Current smokers had a higher rate of post-operative acute respiratory distress syndrome (ARDS) than ex-smokers (p=0.031).](00089-2018.04){#F4}

Current smokers had a significantly higher mortality post-operatively than ex-smokers, with a median post-operative survival of 421 days in current smokers compared with 771 days in ex-smokers (p=0.0225) ([figure 5](#F5){ref-type="fig"}); the log-rank HR was 2.034 (95% CI 1.012--5.298). Patients were followed-up for up to 4 years after surgery, with a significant difference in survival being seen from 9 months post-operatively (ex-smokers two out of 28 (7%) mortality at 9 months *versus* current smokers five out of 14 (36%) mortality at 9 months; p=0.031).

![Post-operative mortality was significantly higher in patients who were current smokers prior to surgery compared with ex-smokers (p=0.0225).](00089-2018.05){#F5}

Discussion {#s4}
==========

This work demonstrates that patients who continue to smoke prior to oesophagectomy have greater post-operative systemic and lung inflammation evidenced by increased numbers of circulating neutrophils, alveolar oedema, and dysregulated concentrations of cytokines in plasma and BAL fluid compared with ex-smokers. Clinically, this translated into worse outcomes with both higher rates of post-operative ARDS and long-term mortality.

Smoking has been linked to an increased risk of ARDS in a variety of conditions, including sepsis and trauma, but the mechanism is not entirely clear \[[@C8], [@C9], [@C14]\]. Smoking has been demonstrated to increase both epithelial and endothelial permeability \[[@C11], [@C12]\], and to be associated with increased alveolar oedema; studies in explanted human lungs found that smokers have more alveolar oedema as measured by lung weight than nonsmokers and that smokers with the highest level of smoke exposure have impaired alveolar fluid clearance \[[@C18]\]. A recent study in healthy volunteers using the lipopolysaccharide challenge model of ARDS suggested that smoking may predispose to an exaggerated disruption of the alveolar--capillary membrane in response to inflammatory insults \[[@C14]\], increasing the permeability of the membrane to protein and replicating findings seen in ARDS. Increased pulmonary permeability appears to be rapidly reversible, with one study demonstrating that the pulmonary epithelial permeability induced by smoking improves within 1 week of smoking cessation \[[@C19]\].

Current smokers in our study had greater levels of inflammatory alveolar oedema as demonstrated by greater post-operative day 1 EVLWI and PVPI, and higher concentrations of IL-1ra and TNFR1, than ex-smokers. Previous studies have demonstrated a higher concentration of BAL IL-1ra and TNFR1 in patients at risk of ARDS, and in those with active ARDS \[[@C20], [@C21]\]. Higher circulating TNFR1 concentrations are also associated with poorer outcomes in patients with ARDS \[[@C22]\]. Meanwhile, BAL VEGF, which acts to protect the pulmonary vasculature and epithelium, was lower in current smokers. Again, low concentrations of BAL VEGF are commonly seen in patients with ARDS \[[@C23], [@C24]\]. In plasma, pre-operative concentrations of soluble ICAM-1, an endothelial cell adhesion molecule that has been shown to be elevated in smokers and associated with poorer prognosis in patients with colorectal cancer \[[@C25], [@C26]\], were greater in current smokers, but there was no significant difference in post-operative levels. Concentrations of IL-17 were lower in current smokers, a finding which has previously been associated with increased susceptibility to bacterial colonisation in the lungs \[[@C27]\]. Taken together, these findings suggest that the dysregulated inflammation in smokers leads to increased alveolar oedema, ARDS and death post-operatively.

To the best of our knowledge, this study is the first to investigate the relationship between pre-operative smoking status and PiCCO measures of peri-operative alveolar oedema. We found that smokers have evidence of dysregulated alveolar inflammation in the peri-operative period as a direct effect of surgical trauma, which may explain the increased risk of post-operative ARDS. Our finding that risk of pneumonia was similar in both groups suggests that the increased risk of ARDS in smokers undergoing oesophagectomy is not a result of increased susceptibility to pulmonary infection, but perhaps due to a dysregulated response to inflammatory insult.

We found that ex-smokers survive on average almost 1 year longer (350 days) following oesophagectomy than current smokers. We were unable to access death certificate records to establish the cause of death for our patients, but it is likely to include recurrence of the oesophageal cancer and infection. Patients diagnosed with ARDS have increased mortality for at least 2 years following recovery from their acute illness \[[@C28]\], so the increased incidence of ARDS we found in current smokers may directly contribute to increased long-term mortality. There is little data available on the effects of ARDS upon long-term immunoparesis, but studies in patients with sepsis have demonstrated marked effects on the adaptive immune system that may increase susceptibility to development of disease in the future \[[@C29], [@C30]\].

This study does have limitations. First, it is likely that some differences between groups are obscured by the small number of patients studied. The patients in this study only had post-operative BAL performed, so we were not able to investigate smoking-related changes from pre-operative BAL prior to oesophagectomy. Furthermore, data related to modes of ventilation, ventilator settings and lung protective ventilation during anaesthesia were not collected in these patients, all of which may play a role in decreasing the rate of post-operative complications and mortality. In addition, patients self-reported their smoking status and we were not able to carry out any biochemical confirmation (*e.g.* exhaled carbon monoxide and salivary cotinine), which may have increased the accuracy of the assessment \[[@C31]\]. We do not know the length of time since smoking cessation for the group of ex-smokers and it is likely that the range is relatively broad. Data regarding smoking status were collected at the pre-operative assessment clinic (typically up to 2 weeks prior to surgery) and self-reported, so it is possible that some short-term quitters were included in the current smokers group. There is little consensus on the optimal minimal time prior to surgery for cessation; while studies have shown that airway sensitivity is reduced within 1--2 days of abstinence from smoking \[[@C32]\], others suggest that a period of time ranging from 1 to 6 months is required to see a reduction in post-operative pulmonary complications \[[@C33]--[@C37]\]. While some studies have suggested an increased risk of harm when smokers abstain or reduce cigarette consumption close to surgery, this has not been confirmed on meta-analysis, although the number of patients involved in such studies is relatively small \[[@C36], [@C38]\].

Conclusions {#s4a}
-----------

This study demonstrates that patients who smoke at the time of oesophagectomy have altered pulmonary immune markers post-operatively, with higher levels of inflammatory mediators, and lower levels of protective mediators, similar to those seen in established ARDS. These changes translate into a higher post-operative inflammatory alveolar oedema, greater risk of ARDS and greater long-term mortality. Further research is needed to investigate the optimal timing of smoking cessation prior to surgery, and to evaluate the impact that novel nicotine delivery systems such as "e-cigarettes" have on post-operative inflammation and clinical outcomes.
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